Testing effectiveness (Phase 2)Ended earlyNCT04093323
What this trial is testing
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Who this might be right for
HLA-A2 Positive Cells PresentRefractory Melanoma
Roswell Park Cancer Institute 1